Literature DB >> 28785453

Nitrates as a Treatment of Acute Heart Failure.

Mohammad S Alzahri1,2, Anita Rohra1, W Frank Peacock1.   

Abstract

The purpose of this article is to review the clinical efficacy and safety of nitrates in acute heart failure (AHF) by examining various trials on nitrates in AHF. Management of AHF can be challenging due to the lack of objective clinical evidence guiding optimal management. There have been many articles suggesting that, despite a benefit, nitrates are underused in clinical practice. Nitrates, when appropriately dosed, have a favourable effect on symptoms, blood pressure, intubation rates, mortality and other parameters.

Entities:  

Keywords:  Nitrates; acute heart failure; congestive heart failure; inotropes; isosorbide dinitrate; nesiritide; nitric oxide; nitrite; nitroglycerine; pulmonary congestion; pulmonary oedema; vasodilatation

Year:  2016        PMID： 28785453      PMCID： PMC5490950          DOI： 10.15420/cfr.2016:3:3

Source DB:  PubMed          Journal:  Card Fail Rev        ISSN： 2057-7540


  40 in total

1.  2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation.

Authors:  Mariell Jessup; William T Abraham; Donald E Casey; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Marvin A Konstam; Donna M Mancini; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy
Journal:  Circulation       Date:  2009-03-26       Impact factor: 29.690

2.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  Circulation       Date:  2013-06-05       Impact factor: 29.690

3.  Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine.

Authors:  J Dupuis; G Lalonde; R Lemieux; J L Rouleau
Journal:  J Am Coll Cardiol       Date:  1990-10       Impact factor: 24.094

Review 4.  Nitrate therapy: new aspects concerning molecular action and tolerance.

Authors:  Thomas Münzel; Andreas Daiber; Tommaso Gori
Journal:  Circulation       Date:  2011-05-17       Impact factor: 29.690

5.  Impact of a high-dose nitrate strategy on cardiac stress in acute heart failure: a pilot study.

Authors:  T Breidthardt; M Noveanu; M Potocki; T Reichlin; P Egli; S Hartwiger; T Socrates; E Gayat; M Christ; A Mebazaa; C Mueller
Journal:  J Intern Med       Date:  2009-06-22       Impact factor: 8.989

6.  Early vasoactive drugs improve heart failure outcomes.

Authors:  William Frank Peacock; Charles Emerman; Maria R Costanzo; Deborah B Diercks; Margarita Lopatin; Gregg C Fonarow
Journal:  Congest Heart Fail       Date:  2009 Nov-Dec

7.  The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: a propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database.

Authors:  Maria Rosa Costanzo; R S Johannes; Michael Pine; Vikas Gupta; Mitchell Saltzberg; Joel Hay; Clyde W Yancy; Gregg C Fonarow
Journal:  Am Heart J       Date:  2007-08       Impact factor: 4.749

8.  The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis.

Authors:  J G F Cleland; K Swedberg; F Follath; M Komajda; A Cohen-Solal; J C Aguilar; R Dietz; A Gavazzi; R Hobbs; J Korewicki; H C Madeira; V S Moiseyev; I Preda; W H van Gilst; J Widimsky; N Freemantle; Joanne Eastaugh; J Mason
Journal:  Eur Heart J       Date:  2003-03       Impact factor: 29.983

9.  Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT.

Authors:  Jay N Cohn; S William Tam; Inder S Anand; Anne L Taylor; Michael L Sabolinski; Manuel Worcel
Journal:  J Card Fail       Date:  2007-06       Impact factor: 5.712

Review 10.  Acute heart failure syndromes: clinical scenarios and pathophysiologic targets for therapy.

Authors:  Leonardo De Luca; Gregg C Fonarow; Kirkwood F Adams; Alexandre Mebazaa; Luigi Tavazzi; Karl Swedberg; Mihai Gheorghiade
Journal:  Heart Fail Rev       Date:  2007-06       Impact factor: 4.654
View more
  2 in total

1.  A novel soluble guanylate cyclase activator with reduced risk of hypotension by short-acting vasodilation.

Authors:  Toshihiro Sawabe; Toshiki Chiba; Akihiro Kobayashi; Kosuke Nagasaka; Kazuyuki Aihara; Akiyuki Takaya
Journal:  Pharmacol Res Perspect       Date:  2019-03-04

2.  Olinciguat, an Oral sGC Stimulator, Exhibits Diverse Pharmacology Across Preclinical Models of Cardiovascular, Metabolic, Renal, and Inflammatory Disease.

Authors:  Daniel P Zimmer; Courtney M Shea; Jenny V Tobin; Boris Tchernychev; Peter Germano; Kristie Sykes; Ali R Banijamali; Sarah Jacobson; Sylvie G Bernier; Renee Sarno; Andrew Carvalho; Yueh-Tyng Chien; Regina Graul; Emmanuel S Buys; Juli E Jones; James D Wakefield; Gavrielle M Price; Jennifer G Chickering; G Todd Milne; Mark G Currie; Jaime L Masferrer
Journal:  Front Pharmacol       Date:  2020-04-08       Impact factor: 5.810
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.